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ConCise report
Germinal centres in diagnostic labial gland biopsies 
of patients with primary Sjögren’s syndrome are not 
predictive for parotid MALT lymphoma development
erlin A Haacke,1,2 Bert van der Vegt,2 Arjan Vissink,3 Fred K L spijkervet,3 
Hendrika Bootsma,1 Frans G M Kroese1
ABstrAct
Objective patients with primary sjögren’s syndrome 
(pss) have an increased risk of developing non-Hodgkin’s 
lymphoma (nHL), particularly parotid gland mucosa-
associated lymphoid tissue (MALt) lymphomas. presence 
of germinal centres (GCs) in labial gland biopsies has 
been suggested as predictive factor for nHL. We assessed 
whether presence of GCs is increased in labial gland 
biopsies from patients with pss who developed parotid 
MALt lymphoma, the dominant nHL-subtype in pss, 
compared with patients with pss who did not develop 
lymphoma.
Methods eleven labial gland biopsies from patients with 
pss that were taken prior to parotid MALt lymphoma 
development were compared with biopsies of 22 matched 
pss controls (1:2) who did not develop lymphoma. Biopsies 
were evaluated for GCs (H&e and Bcl6).
results Labial gland biopsies of pss MALt lymphoma 
patients, revealed GCs in 2/11 (18%) H&e sections and 
3/11 (27%) Bcl6 stained sections. in controls, GCs were 
present in 4/22 (18%) of H&e sections and 5/22 (23%) 
of Bcl6 stained sections.
conclusion presence of GCs in labial gland biopsies 
does not differ between patients with pss that develop 
parotid MALt lymphoma and patients with pss who do 
not develop lymphoma. the presence of GCs in labial 
gland biopsies is therefore not a predictive factor for 
pss-associated parotid MALt lymphomas.
IntrOductIOn
Primary Sjögren’s syndrome (pSS) is a systemic auto-
immune disease, in which salivary and lacrimal glands 
are affected by a chronic inflammatory process, which 
leads to dryness of mouth and eyes.1 Histopathologi-
cally, this inflammatory process is characterised by a 
periductal lymphoid infiltrate in the glandular paren-
chyma.2 In roughly one quarter of the patients with 
pSS, germinal centres (GCs) can be found within these 
lymphoid infiltrates reflecting the B-cell hyperactivity 
that characterises the disease.3 4 Although the clinical 
significance of these GCs remains to be elucidated, 
the presence of GCs in the glandular tissue of patients 
with pSS is generally associated with more severe clin-
ical disease as reflected by a higher focus score (FS), 
increased presence of anti-SSA/Ro (52 kD + 60 kD) 
and anti-SSB/La autoantibodies and elevated levels of 
proinflammatory cytokines in the blood.3
A serious complication of pSS is the 5%–10% lifetime 
risk of developing non-Hodgkin’s B-cell lymphomas 
(NHL).5 The most common subtype NHL in pSS 
is the mucosa-associated lymphoid tissue (MALT) 
lymphoma.5–7 These MALT lymphomas preferentially 
arise in the parotid glands and account for >60% 
of the lymphomas arising in patients with pSS.6–8 
Which patients with pSS will develop NHL is largely 
unknown, but several predictors have been identified 
including disease activity, persistent glandular enlarge-
ment, lymphadenopathy, palpable purpura, anti-Ro/
anti-La antibodies, rheumatoid factor, lymphopaenia, 
declined C3 or C4 levels, cryoglobulinaemia and an 
FS ≥3 in the labial gland biopsy.9–11 Presence of GCs in 
diagnostic labial gland biopsies has also been proposed 
as a predictive factor for the development of NHL. 
However, in the study underlying this assumption, all 
subtypes of NHL were taken into account, including 
NHL subtypes not typically associated with pSS, such 
as follicular lymphoma and T-cell lymphoma.12 For 
this reason, we explored the predictive role of GCs 
in labial gland biopsies from patients with pSS for 
parotid gland MALT lymphomas.
MAterIAls And MethOds
Patients
From 56 patients with pSS diagnosed with parotid 
MALT lymphoma, we were able to acquire labial 
gland biopsies of 11 patients taken at diagnosis 
of pSS, before (median 4.0, IQR 1.5–6.1 years) 
lymphoma diagnosis (table 1). Labial gland biopsies 
from 22 pSS patients with an NHL free follow-up 
(median 12.0, IQR 6.3–16.8 years) served as controls 
(see online supplementary table S1). Matching of 
control pSS patients (1:2) was based on age at diag-
nosis of pSS and the presence of SSA autoantibodies. 
Patients were frequency-matched within three age 
groups: patients diagnosed with pSS at an age of ≤40, 
between 40 and 60 and ≥60 years. All patients were 
clinically diagnosed as pSS and retrospectively fulfilled 
the ACR-EULAR(American College of Rheumatology 
- European League Against Rheumatism) classifica-
tion) criteria13 at time of diagnosis. Of the 33 included 
patients, 32 also fulfilled the AECG-criteria at time of 
diagnosis. Of one pSS patient this is uncertain due to 
missing sialometry and ocular examination.
histopathological assessment of diagnostic 
salivary gland biopsies
Diagnostic labial salivary gland biopsies were 
formalin fixed, paraffin embedded and sectioned 
at 3 µm thickness. Serial sections were stained 
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with H&E, and immunohistochemically for B-cell lymphoma 
six protein (Bcl6, clone GI191E/A8, Ventana, Illkirch, France) 
and CD45 (clone 2B11+PD7/26, Ventana, Illkirch, France). 
Staining was performed on a Ventana Benchmark platform as 
previously described.14 In H&E stained sections, FS, lympho-
epithelial lesions (LELs) and GCs were assessed. FS was based 
on  the  number  of  clusters  of  ≥50  lymphocytes  (foci)/4 mm2 
parenchyma. In case of multiple large confluent foci, an arbi-
trary FS of 12 was used.15 LELs were defined as a striated duct 
with lymphocytes within its basement membrane. GCs were 
defined as a clearly visible lighter area in a lymphocytic infil-
trate containing cells usually present in classical GCs: follicular 
dendritic cells (FDCs), centrocytes, centroblasts and macro-
phages. Since detection of GCs is difficult in H&E stained 
sections, and small GCs may be overlooked,16 we also evaluated 
GCs in Bcl6 stained sections. Bcl6 is a transcription factor highly 
expressed by all GC B-cells. A cluster of ≥5 adjacent Bcl6+ cells 
within a focus was classified as a GC.
Besides FS, we also measured the extent of glandular inflam-
mation as proposed.2 This was assessed using CD45 staining. 
CD45 is expressed by all lymphoid and non-lymphoid cells of 
hematopoietic origin, allowing easy quantification of the rela-
tive area of the infiltrate. CD45 expression was measured using 
ImageScope V.12.0 (Aperio Technologies). Slides were blinded 
and independently scored by a trained resident (EH) and a dedi-
cated head and neck pathologist (BvdV).
statistical analysis
Mann-Whitney U test and Fisher’s exact test were used accord-
ingly to test differences between groups (IBM-SPSS Statistics 
V.23).
results
Analysis of H&E stained sections from diagnostic labial gland 
biopsies, taken prior to parotid MALT lymphoma development, 
revealed presence of GCs in 2/11 (18%) patients (table 2, online 
supplementary figure 1). Staining for Bcl6 revealed an extra 
(small) GC in a biopsy of one additional patient (figure 1, 
table 2). Thus, in patients with pSS who developed parotid 
MALT lymphoma, GCs were present in 3/11 (27%) prelym-
phoma labial gland biopsies. In the patients with pSS that did 
not develop parotid MALT lymphomas (nor any other type of 
NHL), GCs were detected in 4/22 (18%) diagnostic labial gland 
biopsies in H&E stained sections and in 5/22 (23%) of Bcl6 
stained sections (table 2). This proportion was comparable with 
that seen in patients with pSS who did develop parotid MALT 
lymphoma.
Since FS ≥3 has been suggested as predictive factor for NHL 
development,9 we compared FS and relative area of CD45+ infil-
trate in prelymphoma labial gland biopsies and biopsies from 
control pSS patients. FS did not differ between both groups 
(Mann-Whitney U test, p=0.204). The percentage of biopsies 
with FS ≥3 was even higher in the control group (36% vs 27%). 
The relative area of CD45+ lymphocytic infiltrate, however, 
tended to be higher in the prelymphoma labial gland biopsies 
than in the controls (table 2, online supplementary figure 1).
dIscussIOn
This study shows that the presence of GCs does not differ 
between diagnostic labial gland biopsies from patients with pSS 
who did develop parotid MALT lymphoma and patients with 
pSS who did not develop such lymphoma. In H&E stained 
sections, we observed an identical percentage of GCs in both 
categories of patients (18%). With a more sensitive and specific 
method to identify GCs, viz. staining for the GC B-cell associ-
ated transcription factor Bcl6,16 a slightly higher incidence of 
GCs was seen in both groups: 27% for patients with prelym-
phoma and 23% for non-lymphoma pSS patients. Although the 
two groups of patients with pSS are rather small, the percentages 
of GCs are similar to those reported for labial gland biopsies 
among the general pSS population.3 Based on a large number 
of studies, Risselada et al reported that the mean weighted 
percentage of GCs in labial gland biopsies of patients with pSS 
was 25.1%±5.0% (range 18.3%–33%) in H&E stained sections. 
Since there was no difference in the occurrence of GCs in labial 
gland biopsies of patients with pSS prior to parotid MALT 
lymphoma development and the matched pSS controls as well as 
with the general pSS population, we conclude that presence of 
GCs in labial biopsies is not likely predictive for parotid MALT 
lymphoma development.
Other studies that examined the predictive value of GCs 
in NHL development did not restrict themselves to MALT 
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1 F 37 3.5 2 Labial 4.0 27.6 − + + +
2 F 60 13.7 1 Labial 0.8 5.3 − − − + −
3 F 32 4.0 1 Labial 1.1 12.2 − − − + +
4 F 28 0.2* 1 Labial 0 7.4 − − − + +
5 F 63 6.1 2 Labial 4.7 38.8 + + + + −
6 F 47 3.2 2 Labial 1.8 23.4 − − + + +
7 F 45 0.3* 1 Labial 2.0 34.1 − + + + +
8 F 67 4.6 1 Labial 0 5.3 − − − + +
9 F 31 4.0 2 Labial 1.7 20.3 − − + + +
10 F 51 13.3 3 Labial 2.7 18.2 + + + + −
11 F 61 1.5 1 Labial 4.0 21.6 − − + + −
*Biopsy taken shortly before lymphoma diagnosis. +present. -not present.
Δ*Lymph pSS: time between diagnosis of pSS and parotid MALT lymphoma, Ann Arbor Mushoff: (1) localised disease: lymphoma located in one or more salivary glands, (2) 
locally disseminated: lymphoma localised in one or more salivary glands with one or more enlarged regional lymph nodes (>1 cm), (3) disseminated disease: localisation of 
lymphoma in one or more salivary glands, with one or more enlarged regional lymph nodes (>1 cm) and/or bone marrow, spleen, liver or other extra nodal site than the salivary 
gland, or localisation of lymphoma in multiple extra nodal sites.20
Bcl6, B cell lymphoma 6; FS, focus score; GC, germinal centre; LEL, lymphoepithelial lesions; MALT, mucosa-associated lymphoid tissue.
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lymphoma.9 12 17 In a retrospective analysis of prelymphoma 
labial gland biopsies from 13 pSS patients with unspecified NHL 
lymphomas, Risselada et al9 found that in H&E stained sections, 
GCs were present in only three (23%) of the patients. Johnsen 
et al17 showed that in similarly stained labial gland biopsies of 
pSS NHL patients, 4 out of 12 biopsies (33%) exhibited GCs. 
The matched control group of pSS patients without malignant 
lymphoma development showed an even higher percentage of 
46% (13/28) GCs in the biopsies. However, in Johnsen’s study, 
biopsies were taken prior to NHL development and simultane-
ously or even after NHL development.
In contrast to our findings and the aforementioned reports, 
two earlier studies (Theander et al12 and Bombardieri et al18) 
indicated an increased incidence of GCs in diagnostic biopsies 
preceding NHL development. Theander et al observed that 
six out of seven patients had GCs in diagnostic labial salivary 
gland biopsies, prior to NHL development. Besides differences 
in patient cohorts, the most likely explanation for the apparent 
discrepancy between Theander’s study and our findings might 
be the selection of patients with pSS that developed NHL. 
While Theander et al took all NHLs into account, we restricted 
ourselves to NHLs that are typically associated with pSS, namely 
parotid MALT lymphomas. Remarkably, only one out of seven 
pSS lymphomas in Theander’s retrospective study represented 
a salivary gland (parotid) MALT lymphoma, making compar-
ison with our study difficult. Bombardieri et al18 found ‘GC-like 
structures’ in six out of eight (75%) of labial gland biopsies from 
pSS and patients with secondary Sjögren’s syndrome preceding 
parotid MALT lymphoma. However, in this study, GC-like struc-
tures were determined by the presence of T-cells, B-cells and 
CD21+ FDC networks. Although CD21+ FDC networks are a 
prerequisite for GC development, their presence does not imply 
that GCs are indeed present. This may lead to a significant over-
estimation of the number of GCs in the tissue compared with 
Bcl6 staining.16 19
In conclusion, there are no indications that the occurrence of 
GCs in diagnostic labial gland biopsies is increased in patients 
with pSS who developed parotid MALT lymphoma. Thus, in our 
opinion, labial salivary gland GCs of patients with pSS are not 
likely a predictive factor for parotid MALT lymphoma develop-
ment. Nevertheless, their presence might be of clinical relevance 
for stratification of pSS patients regarding treatment options. 
For this reason, uniform histopathological criteria for the assess-
ment of GCs are eagerly awaited.
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table 2 Patient characteristics and histological results of diagnostic labial gland biopsies from pSS patients developing parotid MALT lymphomas 
and control labial gland biopsies
Variable
labial biopsies prior to parotid 
MAlt lymphoma (n=11)
labial biopsies from patients with pss 
without lymphoma (n=22)
p Value Mann-Whitney u test (MWu) 
or Fisher’s exact test (Ft)
Female n (%) 11/11 (100) 20/22 (91) 0.542 (FT)
Age (year), mean (SD) 47.5 (14.0) 48.7 (17.2) 0.638 (MWU)
Anti-SSA positive, n (%) 11/11 (100) 22/22 (100) -
Anti-SSB positive, n (%) 7/11 (64) 13/22 (59) 1.000 (FT)
Anti-RF positive, n (%) 11/11 (100) 19/22 (86) 0.534 (FT)
Anti-ANA positive, n (%) 11/11 (100) 21/22 (96) 1.000 (FT)
Δ* pSS-lymph (year), median (IQR) 4.0 (1.5–6.1) – –
Δ* pSS-FU (year), median (IQR) – 12.0 (6.3–16.8) –
FS, median (IQR) 1.8 (0.8–4.0) 2.7 (1.4–3.5) 0.204 (MWU)
FS ≥3, n (%) 3/11 (27) 8/22 (36) 1.000 (FT)
Area CD45 (%), median (IQR) 20.3 (7.4–27.7) 12.7 (9.4–19.1) 0.143 (MWU)
LELs based on H&E, n (%) 7/11 (64) 13/22 (59) 1.000 (FT)
GC based on H&E, n (%) 2/11 (18) 4/22 (18) 1.000 (FT)
GC based on Bcl6, n (%) 3/11 (27) 5/22 (23) 1.000 (FT)
Δ*Lymph-pSS: time between diagnosis of pSS and parotid MALT lymphoma.
Δ*pSS-FU: time between diagnosis of pSS and last follow-up.
FU, follow up; Bcl6, B-cell lymphoma 6 protein; FS, focus score; GC, germinal centre; FT, Fisher’s exact test; LEL, lymphoepithelial lesions; MALT, mucosa-associated lymphoid 
tissue; MWU, Mann-Whitney U test; pSS, primary Sjögren’s syndrome; RF, rheumatoid factor.
Figure 1 GCs in diagnostic labial salivary gland biopsies of patients 
with pSS who developed a parotid MALT lymphoma later on. (A) Clearly 
visible GC in a periductal focus of the labial gland , H&E stain. (B) Bcl6 
staining of serial section, showing the same GC. (C) Suspicious GC in 
a periductal focus of the labial gland, H&E stain. (D) Bcl6 staining of 
a serial section shows a small GC. Arrows point to GCs. GCs, geminal 
centres; pSS, primary Sjögren’s syndrome.
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Correction: How common is clinically inactive disease in 
a prospective cohort of patients with juvenile idiopathic 
arthritis? The importance of definition
Dore M, Marlow C, Cares WM, et al. How common is clinically inactive disease in a prospec-
tive cohort of patients with juvenile idiopathic arthritis? The importance of definition. Ann of 
Rheum Dis 2017;76:1381–8.
Figure 1 was corrected online but the incorrect version appeared in the August print issue.
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